Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zonampanel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 known ✓ | P42261 | 5/20 | 0.74 |
| ▸ | GRIA2 known ✓ | P42262 | 5/20 | 0.74 |
| ▸ | GRIA3 known ✓ | P42263 | 5/20 | 0.74 |
| ▸ | GRIA4 known ✓ | P48058 | 5/20 | 0.74 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.98 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.98 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.74 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.74 |
| ▸ | GRIK5 | Q16478 | 5/20 | 0.74 |
| ▸ | GRIK3 | Q13003 | 4/20 | 0.74 |
| ▸ | GRIK4 | Q16099 | 4/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zonampanel SCHEMBL678832 | 0.99 | SLC22A6 (1.00) | SLC22A6SLC22A8GRIA1GRIA2GRIA3 | |
| Zonampanel SCHEMBL29379917 | 0.99 | SLC22A6 (1.00) | SLC22A6SLC22A8GRIA1GRIA2GRIA3 | |
| SCHEMBL8192737 | 0.95 | SLC22A6 (0.92) | SLC22A6SLC22A8GRIA1GRIA2GRIA3 | |
| SCHEMBL7814578 | 0.90 | SLC22A6 (0.84) | SLC22A6SLC22A8GRIA1GRIA2GRIA3 | |
| SCHEMBL8189664 | 0.89 | SLC22A6 (0.82) | SLC22A6SLC22A8GRIA1GRIA2GRIA3 | |
| SCHEMBL8189677 | 0.88 | SLC22A6 (0.79) | SLC22A6SLC22A8GRIA1GRIA2GRIA3 | |
| SCHEMBL30661074 | 0.88 | SLC22A6 (0.79) | SLC22A6SLC22A8GRIA1GRIA2GRIA3 | |
| SCHEMBL8191566 | 0.87 | SLC22A6 (0.78) | SLC22A6SLC22A8GRIA1GRIA2GRIA3 | |
| SCHEMBL8191240 | 0.86 | SLC22A6 (0.77) | SLC22A6SLC22A8GRIA1GRIA2GRIA3 | |
| SCHEMBL7811014 | 0.86 | SLC22A6 (0.77) | SLC22A6SLC22A8GRIA1GRIA2GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1586321-B1 | New use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2008-12-10 | — | — | EP | claimed |
| US-7247610-B2 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI | 2007-07-24 | — | — | US | claimed |
| EP-1586321-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2005-10-19 | — | — | EP | claimed |
| US-20050101597-A1 | Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-05-12 | — | — | US | claimed |
| US-20050054619-A1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2005-03-10 | — | — | US | claimed |
| WO-2005007106-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A NON-NMDA GLUTAMATE MODULATOR FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2005-01-27 | — | — | WO | claimed |
| US-6797692-B1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2004-09-28 | — | — | US | claimed |
| EP-1370240-A4 | NEUROPROTECTANTS FORMULATIONS AND METHODS | NEURON THERAPEUTICS INC (US) | 2004-09-22 | — | — | EP | claimed |
| EP-1370240-A1 | NEUROPROTECTANTS FORMULATIONS AND METHODS | Neuron Therapeutics, Inc. (US) | 2003-12-17 | — | — | EP | claimed |
| US-20020193285-A1 | Neuroprotectants formulations and methods | NEURON THERAPEUTICS | 2002-12-19 | — | — | US | claimed |
| WO-2002078670-A1 | NEUROPROTECTANTS FORMULATIONS AND METHODS | NEURON THERAPEUTICS, INC. (US) | 2002-10-10 | — | — | WO | claimed |
| EP-1124553-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | Ikonomidou, Hrissanthi (DE) | 2001-08-22 | — | — | EP | claimed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | claimed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | claimed |
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2025-09-18 | — | — | US | disclosed |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | PARIS SCIENCES ET LETTRES (FR) | 2025-06-03 | — | — | US | disclosed |
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2020-05-28 | — | — | US | disclosed |
| EP-1370240-A1 | NEUROPROTECTANTS FORMULATIONS AND METHODS | Neuron Therapeutics, Inc. (US) | 2003-12-17 | — | — | EP | disclosed |
| EP-1316313-A2 | Composition for the treatment of ischemic stroke containing zonampanel and a tissue plasminogen activator | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-06-04 | — | — | EP | disclosed |
| WO-2002078670-A1 | NEUROPROTECTANTS FORMULATIONS AND METHODS | NEURON THERAPEUTICS, INC. (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | GRIA1 346/4885GRIA2 127/4885GRIA3 170/4885 |
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | GRIA1 346/4885GRIA2 127/4885GRIA3 170/4885 |
| US-20050101597-A1 | Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage | GRIN1, GRIN2A, GRIN2B | GRIA1 21/4885GRIA2 11/4885GRIA3 20/4885 |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | NLN, CLN6, SLC1A2 | GRIA1 346/4885GRIA2 127/4885GRIA3 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.